{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:51:22Z","timestamp":1782449482273,"version":"3.54.5"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antineoplastic agents significantly contribute to drug-induced liver injury (DILI). This study evaluates magnesium isoglycyrrhizinate (MgIG) for preventing DILI in hematological malignancy patients receiving novel antitumor therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter retrospective analysis included hematological malignancy patients treated with hepatoprotective agents across 13 Chinese centers (December 2023\u2013February 2024). Primary outcomes assessed liver injury incidence and severity at 21, 30, and 60 days; secondary outcomes evaluated safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Propensity score-matched cohorts (MgIG = 324, control = 182) showed balanced baselines. MgIG recipients had higher chemotherapy (91.4 vs. 64.3%,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001) and Venetoclax exposure (26.2 vs. 2.2%,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Baseline AE incidence was higher with MgIG (4.6 vs. 0.5%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.014), but subsequent follow-ups showed comparable AE rates. Hepatic injury incidence was similar (4.2 vs. 4.0%,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;gt; 0.05). Controls exhibited greater ALT, AST and \u03b3-GGT elevations at day 30 and \u03b3-GGT elevation at day 60 (all\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). MgIG reduced overall hepatic AEs (48.0 vs. 66.7%,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), driven by fewer grade 1\u20132 abnormalities (43.5 vs. 60.3%,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), though grade \u22652 events remained comparable. Interim assessments revealed higher hepatic AE rates in controls at day 21 (54.5 vs. 37.1%) and day 30 (55.7 vs. 34.1%;\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), with elevated grade \u22652 AEs by day 60 (18.6 vs. 8.6%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.022).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Prophylactic MgIG attenuates antineoplastic therapy-induced ALT\/AST\/TBiL elevations in hematological malignancies, demonstrating hepatoprotective efficacy. While its impact on overall DILI incidence remains unclear, longitudinal data suggest clinically meaningful mitigation of hepatotoxicity severity in high-risk subgroups during critical phases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1759611","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:37:58Z","timestamp":1782448678000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Multicenter study on magnesium isoglycyrrhizinate preventing novel antitumor-induced liver injury in hematological malignancies"],"prefix":"10.3389","volume":"13","author":[{"given":"Chen","family":"Liang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongli","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglin","family":"Yang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiming","family":"Pang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Han","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","article-title":"First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study","volume":"28","author":"Shi","year":"2017","journal-title":"Ann Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation","volume":"72","author":"Peeraphatdit","year":"2020","journal-title":"Hepatology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3760\/cma.j.issn.1007-3418.2020.02.016","article-title":"Hepatotoxicity associated with tumor immune checkpoint inhibitors","volume":"28","author":"Lei","year":"2020","journal-title":"Chin J Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3760\/cma.j.issn.0253-2727.2021.03.002","article-title":"Consensus of Chinese experts on prevention and standardized treatment of drug-induced liver injury in patients with blood diseases (2021)","volume":"42","year":"2021","journal-title":"Chin J Hematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.19528\/j.issn.1003-3548.2018.01.047","article-title":"Magnesium Isoglycyrrhizinate combined with Reduced Glutathione for the prevention of hepatic injury induced by high-dose chemotherapy in acute leukemia","volume":"38","author":"Zhang","year":"2018","journal-title":"Clin Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3969\/j.issn.1674-6449.2019.04.020","article-title":"Efficacy of prophylactic use of magnesium isoglycyrrhizinatein treating or preventing liver damage induced byneoadjuvant chemotherapy for breast cancer treatment","volume":"39","author":"He","year":"2019","journal-title":"Health Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.14009\/j.issn.1672-2124.2021.03.018","article-title":"Systematic review of efficacy and safety of magnesium isoglycyrrhizinate in the prevention of liver injury induced by chemotherapy","volume":"21","author":"Wu","year":"2021","journal-title":"Eval Anal Drug Use Hosp"},{"key":"B13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3760\/cma.j.cn501113-20230419-00176-1","article-title":"Chinese guideline for diagnosis and management of drug-induced liver injury (2023 version)","volume":"31","year":"2023","journal-title":"Chin J Hepatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3969\/j.issn.1001-5094.2013.04.003","article-title":"Progress in the pharmacological and clinical researches of magnesiumisoglycyrrhizinate in prevention and treatment of drug-induced liver injury","volume":"37","author":"Jin","year":"2013","journal-title":"Prog Pharm Sci."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.12010\/j.issn.1673-5846.2022.12.010","article-title":"Efficacy and safety of magnesium isoglycyrrhizinate injection in the treatment of drug-inducedliver injury","author":"Jiang","year":"2022","journal-title":"Chin J Pharm Econ."},{"key":"B16","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3892\/ol.2025.14882","article-title":"Preoperative pembrolizumab-induced hemophagocytic lymphohistiocytosis in a patient with breast cancer: a case report","volume":"29","author":"Kawamura","year":"2025","journal-title":"Oncol Lett."},{"key":"B17","doi-asserted-by":"publisher","first-page":"502135","DOI":"10.1016\/j.medin.2024.502135","article-title":"What should intensivists know about immune checkpoint inhibitors and their side effects?","volume":"49","author":"Zlatkov","year":"2025","journal-title":"Med Intensiva"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.21037\/tlcr-24-667","article-title":"A rationale for the poor response to alectinib in a patient with adenocarcinoma of the lung harbouring a STRN-ALK fusion by artificial intelligence and molecular modelling: a case report","volume":"13","author":"Barberis","year":"2024","journal-title":"Transl Lung Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"101408","DOI":"10.1016\/j.gendis.2024.101408","article-title":"Triplet therapy overcomes 3rd-EGFR TKI-resistant EGFR-L858R\/T790M\/C797S in trans and in cis\/L718Q mutation","volume":"12","author":"Ding","year":"2025","journal-title":"Genes Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1453595","DOI":"10.3389\/fphar.2024.1453595","article-title":"Difficulty in differentiating liver injury from an immune checkpoint inhibitor from chemotherapy","volume":"15","author":"Lou","year":"2024","journal-title":"Front Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1111\/bcp.16184","article-title":"Clinical characteristics and prognosis of liver injury induced by immune checkpoint inhibitors in patients with malignancies: a real-world retrospective study","volume":"90","author":"Jiang","year":"2024","journal-title":"Br J Clin Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12876-022-02121-3","article-title":"Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature","volume":"22","author":"Studentova","year":"2022","journal-title":"BMC Gastroenterol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/1759-7714.13416","article-title":"Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis","volume":"11","author":"Koshikawa","year":"2020","journal-title":"Thorac Cancer."},{"key":"B24","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jhep.2010.04.029","article-title":"Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury","volume":"53","author":"Bechmann","year":"2010","journal-title":"J Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1136\/gut.2008.163675","article-title":"Diagnosis, management and prevention of drug-induced liver injury","volume":"58","author":"Verma","year":"2009","journal-title":"Gut."},{"key":"B26","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1177\/1636.17908","article-title":"The role of tiopronin for the prevention of chemotherapy-related liver toxicity in advanced colorectal cancer patients treated with mFOLFOX7: a prospective analysis","volume":"100","author":"Li","year":"2014","journal-title":"Tumori."},{"key":"B27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.14218\/JCTH.2014.00005","article-title":"An update on treatment of drug-induced liver injury","volume":"2","author":"Giordano","year":"2014","journal-title":"J Clin Transl Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3760\/cma.j.issn.1007-3418.2015.03.010","article-title":"Magnesium isoglycyrrhizinate prevention of chemotherapy-induced liver damage during initial treatment of patients with gastrointestinal tumors","volume":"23","author":"Yan","year":"2015","journal-title":"Zhonghua Gan Zang Bing Za Zhi."},{"key":"B29","first-page":"4755","article-title":"Magnesium isoglycyrrhizinate protects hepatic L02 cells from ischemia\/reperfusion induced injury","volume":"7","author":"Huang","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3760\/cma.j.cn114798-20240408-00225","article-title":"Chinese guideline for diagnosis and management of drug-induced liver injury in primary care (2024)","year":"2024","journal-title":"Chin J Gen Pract."},{"key":"B31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.19613\/j.cnki.1671-3141.2019.07.087","article-title":"Clinical efficacy observation of magnesium isoglycyrrhizinate in the treatment of drug-induced liver injury","author":"Jiang","year":"2019","journal-title":"World Latest Med Inform"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1759611\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:38:10Z","timestamp":1782448690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1759611\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":31,"alternative-id":["10.3389\/fmed.2026.1759611"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1759611","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"article-number":"1759611"}}